

HEDIS HINTS – SPD

- Statin Therapy for Patients with Diabetes (SPD)

What are the Measures?

These measure focuses on the importance of appropriate administration and adherence of statin therapy.

- Percentage of members 40-75 years of age with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria:
 - Received Statin Therapy: members who were dispensed at least one statin medication (any intensity).
 - Statin Adherence: members who remained on a statin medication of any intensity for at least 80% of the treatment period during the calendar year.

Why are these measures important?

Statins are a class of drugs that lower blood cholesterol. American College of Cardiology and American Heart Association (ACC/AHA) guidelines state that statins of moderate or high intensity are recommended for adults with established clinical ASCVD. The American Diabetes Association and ACC/AHA guidelines also recommend statins for primary prevention of cardiovascular disease in patients with diabetes, based on age and other risk factors. Guidelines also state that adherence to statins will aid in ASCVD risk reduction in both populations.

How can I improve my HEDIS scores?

- Prescription is submitted and MCO receives the pharmacy claims for high intensity or moderate intensity statin medication during the measurement year
- MCO receives the pharmacy claims for a high intensity or moderate intensity statin medication throughout the measurement year that will total 80% compliance.
- Ensure there is documentation in the medical record related to exclusion criteria per ICD-10 Coding and submit as a claim.

High Intensity Statins	Moderate Intensity Statins
<ul style="list-style-type: none"> • Atorvastatin 40-80 mg • Amlodipine-atorvastatin 40-80 mg • Ezetimibe-atorvastatin 40-80-mg • Rosuvastatin 20-40 mg • Simvastatin 80 mg • Ezetimibe-simvastatin 80 mg 	<ul style="list-style-type: none"> • Atorvastatin 10-20 mg • Amlodipine-atorvastatin 10-20 mg • Ezetimibe-atorvastatin 10-20 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg • Ezetimibe-simvastatin 20-40 mg • Niacin-simvastatin 20-40 mg • Sitagliptin-simvastatin 20-40 mg • Pravastatin 40-80 mg • Lovastatin 40 mg • Niacin-lovastatin 40 mg • Fluvastatin XL 80 mg • Fluvastatin 40 mg bid • Pitavastatin 204 mg

Exclusions

Exclude members who meet any of the following criteria:

- Cardiovascular disease diagnosis coding
 - Discharged from an inpatient setting with an MI
 - Discharged from an inpatient setting with a CABG
 - PCI in any setting
 - Other revascularization in any setting
 - Ischemic vascular disease (IVD) diagnosis at one outpatient visit or one acute inpatient encounter
- Pregnancy diagnosis coding during the measure year or year prior
- In vitro fertilization in the measurement year or year prior
- Dispensed at least one prescription for estrogen agonist (clomiphene) during the measurement year or year prior.
- ESRD diagnosis coding during the measurement years or year prior.
- Cirrhosis diagnosis coding during the measure year or year prior.
- Myalgia, myositis, myopathy, or rhabdomyolysis diagnosis coding during the measurement year.

Reference: National Committee for Quality Assurance. (2018). HEDIS 2019 Volume2 Technical Specifications for Health Plans Washington, DC 20005: American Medical Association. Pg. 169-176.